Fountainhead AM LLC Purchases Shares of 19,151 Pfizer Inc. (NYSE:PFE)

Fountainhead AM LLC acquired a new stake in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 19,151 shares of the biopharmaceutical company’s stock, valued at approximately $551,000.

A number of other hedge funds also recently made changes to their positions in the business. Briaud Financial Planning Inc bought a new position in shares of Pfizer in the 3rd quarter valued at about $30,000. GoalVest Advisory LLC boosted its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer during the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC raised its holdings in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock traded up $0.06 during midday trading on Tuesday, reaching $26.32. The company had a trading volume of 24,286,365 shares, compared to its average volume of 42,105,117. The company has a market capitalization of $149.04 billion, a price-to-earnings ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The stock has a 50 day moving average price of $27.07 and a 200-day moving average price of $28.52. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.14 earnings per share. Equities research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Finally, Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.